


We are the only PARKINSON'S FOUNDATION CENTER OF EXCELLENCE in the region with comprehensive care including doctors specialized in the diagnostics, treatment, research, and education of Parkinson's disease. We have a large multi-disciplinary team including healthcare professionals specialized in Parkinson's disease in the areas of psychology, speech, physical therapy, occupational therapy, dietetics, social work, pharmacy, neuropsychology, and neurosurgery, including a large deep brain stimulation program.

Welcome Dr. Andrea Lee, Movement Disorder Specialist, to the Parkinson's Disease and Movement Disorder Team!

Dr. Lee spent the past 13 years in New York City earning her MD from SUNY Downstate, completing neurology residency and Parkinson's/Movement Disorders fellowship training at NYU, and working as an assistant professor of neurology at Weill Cornell before moving to Kansas this summer. Her focus in PD includes medication management, diet and exercise, and other lifestyle modifications to ensure quality of life and mobility for her patients. She conducts research to better diagnose, treat, and slow/halt progression of PD. She has expertise in the management of Essential Tremor, and is an experienced injector of botulinum toxin for cervical dystonia, hemifacial spasm, drooling (sialorrhea), and blepharospasm. Outside of work, she enjoys spending time with her husband (a Kansas native), 5 month old baby boy Charlie, and dog Buddy.



RAJESH PAHWA, MD
Laverne & Joyce Rider
Professor of Neurology
Director, Parkinson's
Disease and Movement
Disorder Center



KELLY LYONS, PhD
Research Professor
of Neurology
Director, Research and
Education, Parkinson's Disease
and Movement Disorder Center

TREMOR CORNER

ET Studies Ongoing!

JZP385 - Moderate to severe arm/hand tremor. Cannot be taking ET medications.

PRAX-944 - ET for at least 3 years with at least moderate arm/hand tremor. Cannot be taking primidone.

SAGE-324 - ET for at least 3 years with at least moderate arm/hand tremor. Cannot be taking other ET medications.

To participate in a research study or for more information, email pdetcenter@kumc.edu or call 913-588-7159.

**Join the 2022 Virtual Education Conference
October 29, 2022 presented by the IETF
REGISTER HERE!**

Visit www.essentialtremor.org for more information about programs and information for persons with ET!

CLINICAL STUDIES RECRUITING

We have multiple ongoing & upcoming studies for PD. We are currently enrolling for the following studies:

- Newly diagnosed PD patients - Possible disease slowing**
 - UCB0599** - PD patients diagnosed < 2 yrs, never taken PD medications
 - K0706** - PD patients diagnosed < 3 years and not taking any PD medications
 - CVL-751** - PD patients diagnosed for < 3 years and taking no PD medications except for an MAO-B inhibitor
- Stable PD patients**
 - PADOVA** - PD patients taking only an MAO-B inhibitor OR levodopa diagnosed within the last 3 years
 - STEM-PD** - Moderate non-motor symptoms affecting daily activities
- PD patients experiencing OFF time (poor control of symptoms) during waking hours**
 - AMDC-009-103** - PD patients experiencing OFF time, on demand inhalation therapy for OFF episodes
 - CVL-751** - PD patients with at least 2.5 hours of OFF time per day
- PD patients experiencing troublesome dyskinesia**
 - BK-JM-201** - PD patients with at least 1.5 hours of troublesome dyskinesia daily and not taking or willing to stop amantadine
- PD Patients with Mild Cognitive Impairment**
- PD Generation Mapping the Future of Parkinson's Disease** - Testing for 7 genes that have been shown to increase the risk of developing Parkinson's disease. Anyone diagnosed with Parkinson's disease in our region can participate in person or virtually.
- The Parkinson's Progression Markers Initiative (PPMI)**
 - Parkinson's Disease cohort (PD diagnosed within the last 2 years, not on or expected to need meds for 6 months)
 - Prodromal cohort (1st degree relative with PD, REM sleep behavior disorder (RBD), or known genetic variants; 60+ years of age),
 - Healthy Controls (30+ years of age).

If you are interested or have patients who are interested in more information about any of these studies, please email PDETCenter@kumc.edu or call 913-588-7159.

RESEARCH HIGHLIGHT

Parkinson's Disease Mild Cognitive Impairment (PD-MCI)

PD-MCI is a gradual decline in cognitive abilities reported by the person with PD, their caregiver/family or observed by the a healthcare professional, that is not caused by normal aging or other medical conditions such as stroke, depression, head trauma, or medication side effects. PD-MCI is not dementia, although it can be a precursor to dementia. Typically, declines are present on formal testing, but do not interfere significantly with the ability to perform daily activities or with the individual's independence. The types of problems seen with PD-MCI may include difficulty organizing and planning, trouble paying attention, switching focus or shifting between activities, the need to re-read for proper understanding, and difficulty following multi-step directions.

There are currently no approved medications for the treatment of PD-MCI. SAGE-718 is currently being studied as a potential treatment for PD-MCI. It is a positive allosteric modulator of the NMDA receptor, whose activity is essential for learning, memory, and cognition.

If you have PD, experiencing MCI and interested in participating in a research study focusing on mild cognitive impairment, please email PDETCenter@kumc.edu or call 913-588-7159.

Visit our website: KUMC.EDU/PARKINSON for PD information